Name: Hubei Clinical Research Center of Precision Drug Use for Major Diseases
Person in Charge: Zhang Yu
Brief Introduction: The center is a basic research and promotion and application institution of multi-disciplinary and multi-field cooperation, affiliated to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, which is led by the Department of Pharmacy, a national key specialty construction unit of clinical pharmacy, and integrates the national key disciplines related to major diseases (including Cardiovascular Surgery, Cardiovascular Medicine and Urology) and clinical key specialties (Cancer Center), as well as the double first-class A+ discipline "School of Public Health" of Huazhong University of Science and Technology, staring with main treatment drugs (including anti-tumor drugs, anti-thrombotic drugs and anti-rejection drugs) for malignant tumors, serious cardiovascular and cerebrovascular diseases, organ transplantation and other major diseases, based on the research of pharmacogenomics, transcriptomics, proteomics, metabolomics, population pharmacokinetics/pharmacodynamics, pharmacoanalysis, bioinformatics, statistics, etc., and using information technology, artificial intelligence and other technical means to carry out the following research: 1. further improve the biobank of major diseases and establish a large medical database; 2. use multi-omics technology to explore biomarkers for precision drug use; 3. based on big data, build a prediction model of precision medication for major diseases; 4. rely on the information system and artificial intelligence to develop a clinical medication decision support system for precision medication of major diseases; 5. build a standardized precision medication system for major diseases, promote the system and make optimization, designed to push forward the transformation from the "one-size-fits-all" traditional model to the "individualized and customized" precision model for major diseases.
Achievements: Since its establishment in 2020, the center has obtained 6 NSFC projects, published 76 academic papers, including 45 SCI papers, declared 4 invention patents, and successfully applied for approval of 20 new technologies and businesses. At present, the construction of a clinical decision support system for accurate dose prediction of tacrolimus for organ transplantation has been completed, and the related application and promotion are under way.
